ବେଲୁମୋସୁଡିଲ

ବେଲୁମୋସୁଡିଲ
Clinical data
Trade names	Rezurock, Rholistiq
Synonyms	KD025, SLx-2119
AHFS/Drugs.com	monograph
data	US DailyMed: Belumosudil;
Pregnancy; category	AU: D ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ;
Identifiers
	IUPAC name 2-[3-[4-(1H-Indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide;
Chemical and physical data
Formula	C26H24N6O2
Molar mass	୪୫୨.୫୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5;
	InChI InChI=InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31) ; Key:GKHIVNAUVKXIIY-UHFFFAOYSA-N ;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Belumosudil

ବେଲୁମୋସୁଡିଲ (ଇଂରାଜୀ ଭାଷାରେ Belumosudil), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ରେଜୁରୁକ୍ ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା କ୍ରନିକ୍ ଗ୍ରାଫ୍ଟ ବନାମ ହୋଷ୍ଟ ରୋଗ (cGvHD) ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ଏହା ଅତି କମରେ ୧୨ ବର୍ଷ ବୟସ ହୋଇଥିଲେ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁମାନଙ୍କର ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ସତ୍ତ୍ୱେ ଉନ୍ନତି ହୁଏ ନାହିଁ ।^[୫] ଏହା ପାଟିରେ ଦିଆଯାଏ ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, ଦୁର୍ବଳତା, ଅଇ, ତରଳ ଝାଡ଼ା, ଅଣନିଶ୍ୱାସ, କାଶ, ଫୁଲା, ରକ୍ତସ୍ରାବ, ପେଟ ଯନ୍ତ୍ରଣା, ମାଂସପେଶୀ-ଅସ୍ଥି ଯନ୍ତ୍ରଣା, ମୁଣ୍ଡବିନ୍ଧା, କମ୍ ଫସଫେଟ୍, ସ୍ୱଳ୍ପ ଲିମ୍ଫୋସାଇଟ୍ ଏବଂ ଉଚ୍ଚ ରକ୍ତଚାପ ହୋଇପାରେ ।^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୫] ଏହା ଏକ କାଇନେଜ ପ୍ରତିବନ୍ଧକ; ବିଶେଷ ଭାବରେ ଆରଏଚଓ-ଜଡ଼ିତ କଏଲ୍ଡ-କଏଲ କାଇନେଜ ୨ (Rho-associated coiled-coil kinase 2/ ROCK2) । ^[୭]

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ବେଲୁମୋସୁଡିଲ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏହା ଅନୁମୋଦିତ ହୋଇଥିବା ବେଳେ ଏହା ୨୦୨୨ ସୁଦ୍ଧା ୟୁରୋପର ଅନ୍ୟାନ୍ୟ ସ୍ଥାନରେ ହୋଇନାହିଁ ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ମାସକୁ ଏହ ବାବଦ ପ୍ରାୟ ୧୭,୦୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୮] ବ୍ରିଟେନରେ, ଏକ ମାସର ଯୋଗାଣ ୨୦୨୩ ସୁଦ୍ଧା ପାଖାପାଖି ୬୭୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୯]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Rholistiq". Therapeutic Goods Administration (TGA). 26 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
↑ ^୨.୦ ^୨.୧ "AusPAR: Belumosudil". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.
↑ "Archived copy" (PDF). Archived (PDF) from the original on 29 June 2022. Retrieved 29 June 2022.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "Summary Basis of Decision - Rholistiq". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ ^୫.୬ "Rezurock- belumosudil tablet". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.
↑ "FDA approves belumosudil for chronic graft-versus-host disease". U.S. Food and Drug Administration (FDA). 16 July 2021. Archived from the original on 16 July 2021. Retrieved 16 July 2021. This article incorporates text from this source, which is in the public domain.
↑ ^୭.୦ ^୭.୧ "Belumosudil". SPS - Specialist Pharmacy Service. 23 April 2021. Archived from the original on 27 October 2022. Retrieved 29 October 2022.
↑ "Rezurock Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.
↑ "8. Immune system and malignant disease". BNF 86: September 2023 - March 2024. BMJ Group and the Pharmaceutical Press. 2023. pp. 933–934. ISBN 978-0857114617.

[Rholistiq_APM_Summary-1] ୧.୦ ^୧.୧ "Rholistiq". Therapeutic Goods Administration (TGA). 26 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.

[AusPAR:_Belumosudil-2] ୨.୦ ^୨.୧ "AusPAR: Belumosudil". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.

[3] "Archived copy" (PDF). Archived (PDF) from the original on 29 June 2022. Retrieved 29 June 2022.{{cite web}}: CS1 maint: archived copy as title (link)

[4] "Summary Basis of Decision - Rholistiq". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.

[PI2022-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ ^୫.୬ "Rezurock- belumosudil tablet". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.

[FDA2022-6] "FDA approves belumosudil for chronic graft-versus-host disease". U.S. Food and Drug Administration (FDA). 16 July 2021. Archived from the original on 16 July 2021. Retrieved 16 July 2021. This article incorporates text from this source, which is in the public domain.

[SPS2022-7] ୭.୦ ^୭.୧ "Belumosudil". SPS - Specialist Pharmacy Service. 23 April 2021. Archived from the original on 27 October 2022. Retrieved 29 October 2022.

[8] "Rezurock Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.

[BNF86-9] "8. Immune system and malignant disease". BNF 86: September 2023 - March 2024. BMJ Group and the Pharmaceutical Press. 2023. pp. 933–934. ISBN 978-0857114617.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]